Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by 2seventy bio, Inc.

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Announces New Strategic Path Forward
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio to Participate in Upcoming Investor Conference
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Tickers TSVT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.